AAI Councillors Visit Capitol Hill, Extol Value of NIH Research See page 3

N FASEB Celebrates Its Centennial 12 AAI Looks Back—The 1918–1919 In This Issue… on Capitol Hill Influenza Pandemic 2 2012 AAI Election Results N NCATS Forms Industry Partnership 14 2012 AAI Annual Meeting Highlights N Does Your Degree Impact Your ™ 3 Focus on Public Affairs: 22 IMMUNOLOGY 2012 Sponsors NIH Funding Prospects? N AAI Holds Special Session on 24 Grant & Award Deadlines N New Dual Use Research Policy NIH Peer Review 28 Meetings Calendar N NIH Director Collins on TV N AAI Research Advocacy Program Engages 5 Key Partners 7 2012 AAI Advanced Immunology Cover Image: Course Program N FY 2013 NIH Funding Bill Clears Galacidalacidesoxiribunucleicacid Senate Committee 8 Members in the News See page 3 for details. 2012 AAI Election Results AAI congratulates the following members on their election to offices and committees for terms commencing July 1, 2012, and extends a sincere thanks to all candidates for their willingness to run and serve if elected. President (2012–2013) Nominating Committee The American Association Gail A. Bishop, Ph.D. (2012–2013) of Immunologists Carver College of Medicine Pamela S. Ohashi, Ph.D., F.R.S.C., Chair 9650 Rockville Pike Distinguished Professor of Microbiology Senior Scientist and Director Bethesda, MD 20814-3994 and Internal Medicine and Holden Immune Therapy Program Tel: 301-634-7178 Chair of Cancer Biology Ontario Cancer Institute Fax: 301-634-7887 University of Iowa Michael Croft, Ph.D. E-mail: [email protected] www.aai.org Vice-President (2012–2013) Professor and Head, Division of Marc K. Jenkins, Ph.D. Immune Regulation Member Services La Jolla Institute for Allergy Distinguished McKnight Tel: 301-634-7195 and Immunology University Professor E-mail: [email protected] Center for Immunology and JoAnne L. Flynn, Ph.D. Department of Microbiology Professor, Department of Microbiology The Journal of Immunology University of Minnesota Medical School and Molecular Genetics Tel: 301-634-7197 E-mail: [email protected] Secretary-Treasurer (2012–2015) University of Pittsburgh School of Medicine www.jimmunol.org/ Mitchell Kronenberg, Ph.D. Richard M. Locksley, M.D. President and Chief Scientific Officer Investigator, Howard Hughes Council La Jolla Institute for Allergy Medical Institute President and Immunology Sandler Distinguished Professor Gail A. Bishop, Ph.D. Departments of Medicine and Councillor (2012–2016) Microbiology and Immunology Vice President Wayne M. Yokoyama, M.D. University of California, San Francisco Marc K. Jenkins, Ph.D. Investigator, Howard Hughes Mark J. Shlomchik, M.D., Ph.D. Past President Medical Institute Leslie J. Berg, Ph.D. Levin Professor of Medicine and of Professor of Laboratory Medicine Pathology and Immunology and Immunobiology Secretary-Treasurer Washington University School of Yale School of Medicine Mitchell Kronenberg, Ph.D. Medicine Program Committee (2012–2015) Councillors Awards Committee (2012–2015) Shane Crotty, Ph.D. Linda A. Sherman, Ph.D. Dan R. Littman, M.D., Ph.D. Cheong-Hee Chang, Ph.D. Associate Professor, Division of Arlene H. Sharpe, M.D., Ph.D. Professor, Department of Microbiology Vaccine Discovery Wayne M. Yokoyama, M.D. and Immunology La Jolla Institute for Allergy University of Michigan Medical School and Immunology Ex Officio Councillors Jeremy M. Boss, Ph.D. Finance Committee (2012–2015) Erika L. Pearce, Ph.D. Assistant Professor, Department of M. Michele Hogan, Ph.D. Andrea J. Tenner, Ph.D. Pathology and Immunology Leo Lefrançois, Ph.D. Professor and Associate Dean Washington University School of Medicine Paul E. Love, M.D., Ph.D. for Research School of Biological Sciences Publications Committee Executive Director University of California, Irvine (2012–2016) M. Michele Hogan, Ph.D. Ann J. Feeney, Ph.D. www.aai.org/ Professor, Department of Immunology and About/Departments-Staff Microbial Science The Scripps Research Institute

Thank you to all members who invested in their profession and demonstrated their commitment to the AAI mission by voting in the election this year.

2 AAI Newsletter July/August 2012 FOCUS ON PUBLIC AFFAIRS

AAI Holds Special Session on NIH Peer Review

n May 5, 2012, the AAI Committee on Public OAffairs hosted a special session, NIH Peer Review: Understanding the New System, at IMMUNOLOGY 2012™ in Boston. The session provided attendees with an insider view of the current state of peer review at NIH and a look at how the peer review system may evolve in the coming years. of recruiting researchers to serve on study sections and discussed ways that CSR is making it easier for researchers to participate, including conducting more electronic reviews and holding one meeting a year on the West Coast. Nakamura acknowledged the concerns he has heard from AAI and others about the elimination of the A2 application. He noted that CSR is continuing to discuss amended applications, including whether the A2 should be reinstated or whether all amended applications should be eliminated (i.e., accept only NIH peer review session speakers Daniel Rotrosen, Richard “new” applications). Nakamura, Elizabeth Kovacs Daniel Rotrosen described the role of NIAID in The session, which was chaired by Derry NIH peer review, including how program officers at Roopenian, Ph.D., chair of the AAI Committee on NIH institutes can provide assistance to NIH grant Public Affairs (CPA), featured three guest speakers: applicants. Among other things, program officers can Richard Nakamura, Ph.D., acting director of the NIH tell researchers more about the review of their original, Center for Scientific Review (CSR); Daniel Rotrosen, unfunded application if they plan to revise and M.D., director of the Division of Allergy, Immunology, resubmit. Program officers also represent applicants and Transplantation at the National Institute of Allergy before the NIAID Advisory Council. and Infectious Diseases (NIAID); and Elizabeth Kovacs, Finally, Elizabeth Kovacs led a robust question- Ph.D., chair of the AAI Subcommittee on Peer Review and-answer period, which featured much discussion and Grant Submission. about the A2 application. When asked about the 1–9 Richard Nakamura’s presentation focused on the scoring system, Nakamura acknowledged that he has role of CSR in NIH peer review. He explained that CSR heard a number of concerns about this issue, receives all grant applications submitted to NIH but and, when pressed about why CSR can’t go back to a reviews only about 70 percent of those applications. 1–50 scoring system, Nakamura said that CSR might The rest are reviewed by individual institutes and have to consider returning to this scale. centers at NIH. He also talked about the challenge Continued on next page

About the Cover: Also referred to as Homage to Crick Galacidalacidesoxiribunucleicacid and Watson (Discoverers of DNA), the painting reflects Salvador Dalí’s intense interest in science, beginning with (1962–1963) Oil on canvas 1 Planck’s quantum theory in 1940. By the early 1960s, Dalí 120 x 161 /2 inches was fascinated by genetics for the possibility of discovering © Salvador Dalí. Fundación Gala-Salvador Dalí, an intelligent design at work in the universe. This canvas, (Artist Rights Society), 2011 painted early in his “Nuclear Mysticism” period (1962 to 1978), is the artist’s tribute to Francis Crick and James D. Watson for Collection of the Salvador Dalí Museum, Inc., St. Petersburg, FL, 2011. discovering the double helix structure of desoxyribonucleic acid (DNA). The name of the painting incorporates a play on the names of the artist and his wife, Gala, whose back-turned figure displays prominently in the work. www.aai.org AAI Newsletter 3 FOCUS ON PUBLIC AFFAIRS (continued)

AAI Research Advocacy Program Brings Five Key Advocacy Partners to IMMUNOLOGY 2012™

AI hosted its third Research Advocacy Program A(RAP) on May 7, 2012, at the IMMUNOLOGY 2012™ meeting in Boston. The RAP supports the attendance of policy leaders from relevant patient RAP participant Martha Nolan (left) speaking advocacy organizations and foundations at a special to meeting attendees about scientific and program, which provides them opportunity to learn funding opportunities with the Society for Women’s Health Research about basic immunology, meet and hear from leading researchers, discuss policy issues of mutual concern, and develop relationships with AAI and each other. This year, AAI was pleased to host representatives from the American Academy of Pediatrics; the Asthma and Allergy Foundation of America; The Lymphatic Research Foundation; the Society for Women’s Health Research; and Zero—the Project to End Prostate Cancer. The fact that this year’s RAP participants had diverse advocacy goals and strategies allowed for an interesting discussion. The program featured presentations on basic immunology by members of the AAI CPA. The speakers (Clifford Harding, M.D., RAP participant James Baumberger (right) speaking to Ph.D., Introduction to the Immune System; Susanna meeting attendees interested in the pediatric research Greer, Ph.D., Overreactions of the Immune Response; Lori Covey, Ph.D., Harnessing the Immune System to A highlight of the program was its “Meet the Fight Cancer; Elizabeth Kovacs, Ph.D., Immunology Advocacy Partners” roundtable session, during Research: Challenges and Opportunities) effectively which representatives from each of the participating communicated how the immune system relates to groups were available to talk with meeting attendees the diseases of concern to each of the participating about their organizations, including any research organizations. and funding opportunities that might be available.

Senate Committee Increases NIH Budget for FY 2013; House Operating Under Lower Spending Levels

he Senate Appropriations Committee approved The Senate Appropriations Committee bill Tits fiscal year (FY) 2013 appropriations (funding) earmarks much of the $100 million increase by bill for the Departments of Labor, Health and Human providing an additional $56.5 million to the National Services, Education, and Related Agencies (Labor- Center for Advancing Translational Sciences (NCATS), HHS) on June 14, 2012, by a vote of 16-14, on a party for a total NCATS budget of $631.3 million. The Cures line vote (Democrats for, Republicans against). The Acceleration Network (CAN), a program within NCATS, bill includes $30.723 billion for NIH, a $100 million would receive up to $30 million of the $56.5 million increase over last year’s level, and $100 million over increase (for a total CAN budget of $40 million, $10 President Obama’s budget request (which would have million below the president’s requested level). The bill flat-funded the agency). The Committee’s vote follows must still be considered by the full Senate, though no action by the Senate Labor-HHS Appropriations vote had been scheduled by press time. Subcommittee, which approved a similar bill with the same overall NIH funding level.

4 AAI Newsletter July/August 2012 FOCUS ON PUBLIC AFFAIRS

The relevant committees in the House of The day culminated with a reception featuring six Representatives have not yet considered a Labor-HHS guest speakers, including NIH Director Francis Collins, bill for FY 2013. Any such bill will have to comply M.D., Ph.D., and three Nobel laureates. Senator Bob with spending levels previously adopted as a Budget Casey (D-PA) and Representative Chris Van Hollen Resolution by the House Budget Committee and (D-8th, MD) also spoke, thanking FASEB and NIGMS agreed to by the full House on March 29, 2012. The for all they have done to advance biomedical research. House Budget Resolution caps FY 2013 discretionary spending at $1.028 trillion, $19 billion below the level NCATS Forms New Partnership agreed upon in last year’s Budget Control Act (debt- with Industry ceiling agreement). Although the House Budget Resolution does not he newly established NIH National Center for specify how the cuts would be allocated, White House TAdvancing Translational Sciences (NCATS) Office of Management and Budget Acting Director has announced a partnership with Pfizer Inc., Jeffrey Zients has said that the House cuts ($897 billion AstraZeneca, and Eli Lilly to facilitate the availability over 10 years), if distributed equally across the budget, to NIH-funded researchers of pre-existing molecular would greatly harm science. According to Zients, compounds that could potentially be repurposed “[i]nvestments in science, medical research, space, and to create new treatments for patients. The three technology would be cut by more than $100 billion industry partners will initially provide more than 20 over the next decade. The number of new grants from compounds for the program. NIH for promising research projects would shrink The “NIH-Industry Pilot Program: Discovering by more than 1,600 in 2014 and by over 16,000 over a New Therapeutic Uses for Existing Molecules” will decade, potentially curtailing or slowing research to “match discontinued proprietary drug candidates fight Alzheimer’s disease, cancer, and AIDS.” (compounds and biologics) from pharmaceutical After the Senate and House each finalize their own companies with the best ideas from the biomedical bills, a compromise bill will have to be approved by research community for new therapeutic uses.” both chambers before the bill can become law. Although these compounds have already cleared many steps in the development process, including FASEB Celebrates Its Centennial human testing, they have been difficult for researchers to access in the past. In fiscal year 2013, NIH plans on Capitol Hill to provide up to $20 million to support cooperative he Federation of American Societies for research grants under this program. If this pilot TExperimental Biology (FASEB), of which AAI is program is successful, NIH hopes to expand it to a charter member, celebrated its 100th anniversary include additional industry partners and more on May 16, 2012, with a day of advocacy on Capitol compounds. Hill, followed by a centennial reception. The FASEB Via a May Request for Information, NIH sought reception was co-hosted by the National Institute input on how NCATS can most effectively partner of General Medical Sciences (NIGMS), which is with the private sector in this effort. The RFI included celebrating its 50th anniversary. seven questions, including queries related to patent The FASEB celebration included significant and regulatory rights and how success of the program participation by AAI members. AAI members visiting should be measured. Capitol Hill included Fred Finkelman, M.D. (AAI ’76), and three former chairs of the AAI CPA: William Green, Does Your Degree Matter in Ph.D. (AAI ’80); Ellen Kraig, Ph.D. (AAI ’84); and John Obtaining NIH Funding? Schreiber, M.D., M.P.H. (AAI ’91). AAI Director of Public Policy and Government Affairs Lauren Gross, cientists with a Ph.D. are funded at a slightly lower J.D., served as a staff leader for six of the participating Srate than those with either an M.D. or an M.D.- scientists. Ph.D., according to recently released data by Sally Rockey, Ph.D., NIH Deputy Director for Extramural Research. Continued on next page

www.aai.org AAI Newsletter 5 FOCUS ON PUBLIC AFFAIRS (continued)

Rockey analyzed NIH data from 1998 to 2011 to Agencies must determine the risks and benefits of that determine if obtaining a certain degree increases research and use the information gathered to develop one’s chances of getting NIH funding and if those risk-mitigation measures. The new rules apply only to with certain degrees fare better at specific types of unclassified research. institutions. The NIH data show that M.D. scientists The policy is intended both to mitigate potential are funded at a slightly higher rate than Ph.D. risks and to help the federal government “collect scientists. For example, in 2011, the funding rate for information needed to inform the development of an M.D. scientists was 26.3 percent, and the funding updated policy, as needed, for the oversight of DURC.” rate for Ph.D. scientists was 23.9 percent. Researchers with both an M.D. and a Ph.D. fared even better, with Although some are concerned that the new policy a funding rate of 27.1 percent in 2011. According to is too ambiguous and could slow research, NIAID Rockey, this trend has been largely consistent over the Director Anthony Fauci, M.D., said in a recent article last 14 years. in Science (DOI:10.1126/science.336.6077.21) that he thinks the policy will affect a minimal number of When broken down by institution, the NIH data research studies each year. NIAID has just announced show a similar slight advantage for those with an M.D. that it has “placed new terms of award on a very small or M.D. and Ph.D. at higher education institutions and number of grants and contracts that may have dual use independent hospitals, though Ph.D. scientists hold a concerns. Those terms require an institution to assess notable funding-rate advantage at research institutes. the dual use implications of its research and send Further, medical schools, which as a group receive the us a risk mitigation plan. They also ask investigators highest percentage of NIH funding, have nearly equal to share manuscripts with their program officers or funding rates for M.D. and Ph.D. scientists. contracting officer’s representatives before submitting to a journal.” New Federal Government Policy on Dual Use Research NIH Director Collins Appears

n March 29, the NIH Office of Biotechnology on The Colbert Report OActivities released a new government-wide policy arlier this spring, NIH Director Francis Collins, on “dual use research of concern” (DURC), defined by EM.D., Ph.D., appeared on Comedy Central’s the National Science Advisory Board for Biosecurity program The Colbert Report. Host Stephen Colbert as “research that, based on current understanding, discussed with Collins the upcoming HBO series on can be reasonably anticipated to provide knowledge, obesity, The Weight of the Nation. HBO produced the products, or technologies that could be directly series in collaboration with the Institute of Medicine, misapplied by others to pose a threat to public health NIH, the Centers for Disease Control and Prevention, or safety, agricultural crops and other plants, animals, the Michael & Susan Dell Foundation, and Kaiser the environment or materiel.” The policy adds a new Permanente. hurdle for scientists whose funding proposals include the most dangerous pathogens and toxins. To view Dr. Collins’ appearance, please visit www.colbertnation.com/the-colbert-report- The new policy, entitled “United States videos/414123/may-10-2012/francis-collins. You can Government Policy for Oversight of Life Sciences Dual also watch The Weight of the Nation by visiting http:// Use Research of Concern,” requires federal agencies theweightofthenation.hbo.com/films/main-films/ to screen all funding proposals to identify current Consequences. and proposed research that uses (or would use) 15 of the most dangerous biological select agents or toxins.

6 AAI Newsletter July/August 2012 2012 Advanced Course in Immunology July 29–August 3, 2012 • Seaport World Trade Center, Boston, Massachusetts Course Director: Leslie J. Berg, Ph.D., University of Massachusetts Medical School AAI Educational Programs Manager: Mary T. Litzinger, Ph.D.

Don’t miss the premier course in immunology for research scientists! This intensive course is directed toward advanced trainees and scientists who wish to expand or update their understanding of the field. Leading experts will present recent advances in the biology of the immune system and address its role in health and disease. This is not an introductory course; attendees will need to have a firm understanding of the principles of immunology.

Faculty Marc K. Jenkins, Center for Immunology, Arthur Weiss, University of California, University of Minnesota Medical School San Francisco Anatomy of the Immune Response Signaling from Antigen Receptors Christine A. Biron, Brown University Charlotte S. Kaetzel, University of Kentucky Innate Immunity College of Medicine Wayne M. Yokoyama, Washington University Mucosal Immunity School of Medicine JoAnne L. Flynn, University of Pittsburgh NK Cells —Their Receptors and Function School of Medicine in Health and Disease Immune Response to Pathogens Shannon J. Turley, Dana Farber Cancer Pamela S. Ohashi, Ontario Cancer Institute, Institute, Harvard Medical School University of Toronto Dendritic Cells Tolerance Eugene M. Oltz, Washington University Betty A. Diamond, The Feinstein Institute School of Medicine for Medical Research The Generation and Modification Autoimmunity of Lymphocyte Antigen Receptor Genes Robert Schreiber, Washington University Shiv Pillai, Massachusetts General Hospital School of Medicine Cancer Center, Harvard Medical School Tumor Immunology B Cell Development Raif Geha, Children’s Hospital Boston, Ellen A. Robey, University of California, Berkeley Harvard Medical School T Cell Development Immunodeficiencies Ulrich H. von Andrian, Harvard Mary Collins, Pfizer (ret.) Medical School Immunotherapeutics Lymphocyte Trafficking Dan H. Barouch, Beth Israel Deaconess Kenneth L. Rock, University Medical Center, Harvard Medical School of Massachusetts Medical Center Vaccines MHC-Restricted Antigen Presentation to T Cells Also included will be lectures on Mediators Susan M. Kaech, Yale University of Inflammation and Asthma and Allergy. Lymphocyte Memory

For complete course details and registration, visit: www.aai.org/Education/Courses For assistance, contact (301) 634-7178 or [email protected]. Overseas applicants are advised to apply early for visas; for details, visit www.aai.org/Education/ Courses/Visa.html. Financial support for underrepresented minority scientists is available through the FASEB MARC Program; for details, visit http://marc.faseb.org. Members in the News AAI Members Elected to National Academy

Four AAI members are among 83 scientists elected earlier the genomic effects of nuclear transfer cloning, and the this year as members or foreign associates of the National effects of maternal diet on gene expression during the Academy of Sciences (NAS) in recognition of their distin- periparturient period. guished and continuing achievements in original research. Lewin is a past member of the AAI Veterinary AAI members elected this year to the NAS, the elite Immunology Committee and ad hoc reviewer for The corps of researchers representing the country’s and world’s Journal of Immunology. He is a founding co-editor of leading scientific institutions, include Harris Lewin, Yasuko Annual Reviews of Animal and Veterinary Biosciences and Rikihisa, Alexander Rudensky, and Shimon Sakaguchi. serves as an associate editor for Animal Biotechnology, Profiled below, they will be inducted during the academy’s section editor for the Encyclopedia of Genetics, Genomics, 150th annual meeting next April in Washington, DC. Proteomics and Bioinformatics, and on the editorial boards of Physiological Genomics and Annual Reviews Harris A. Lewin, Ph.D., AAI ’89 of Genomics and Human Genetics. His additional University of California, Davis (UC Davis) career appointments and honors include: the Wolf Vice Chancellor of Research; Distinguished Professor, Prize in Agriculture (co-recipient, for work on genetics, Department of Evolution and Ecology genomics, and disease resistance in cattle); elected fellow, American Association for the Advancement of Science; AsA vice chancellor for research elected foreign member, the Royal Swedish Academy of sinces 2011, Harris Lewin Agriculture and Forestry; chair, scientific advisory board, overseeso the UC Davis Office GenoMar AS (a Norwegian aquaculture and biotechnology ofo Research, organizing and company); founder and science advisory board member, promotingp research on campus, Pyxis Genomics; member, American Association of managingm grant applications, Veterinary Immunologists Nominating Committee; anda overseeing intellectual elected member, Standing Committee on the Genetic property,p technology transfer, Basis of Immune Responsiveness, International Society for anda efforts to translate UC Davis Animal Genetics; review panel member, U.S. Department discoveriesd into new companies of Agriculture (USDA) Competitive Grants Program anda products. (Growth and Development Section); member, National Harris Lewin Holder of the Robert and Animal Genome Research Program Database Committee; Rosabel Osborne Endowed Chair peer review panel member, USDA/Cooperative State in the Department of Evolution and Ecology, Lewin is also Research Service National Research Initiative Competitive a member of the UC Davis Genome Center, where he and Grants Program (Animal Molecular Genetics and Gene his laboratory colleagues continue his research on genome Mapping); external reviewer, Institute for Animal Health, evolution. Biotechnology and Biological Research Council (UK); chair, USDA Committee on Animal Genome Database Lewin studies mammalian comparative and functional System; advisory board member (Biosciences Division), genomics, addressing the evolution of mammalian Argonne National Laboratory; and program committee genomes and the role of chromosome rearrangements member, 2010 Biotechnology Industry Organization. in adaptation, speciation, and the origins of cancer. His work has led to the discovery of a gene responsible for An animal sciences graduate of Cornell University, susceptibility to bovine leukemia virus infection and to where he earned a master’s degree in animal breeding and the development of high-density comparative maps for genetics, Lewin received his Ph.D. in immunology from the cattle and human genomes, as well as novel software UC Davis. Before his return to UC Davis last year, Lewin for in silico gene mapping using the human genome as spent 27 years at the University of Illinois (UI) at Urbana- a template. Additionally, his group produced the first Champaign, where he served most recently as the E.W. and large-scale cDNA microarray and oligoarray for functional J.M. Gutgsell Endowed Professor of Immunogenetics in the genomics of ruminants. These tools have been used to Department of Animal Sciences and as a member of the study mammary gland development and involution, Center for Advanced Study.

8 AAI Newsletter July/August 2012 Lewin began his UI faculty career as an assistant (bacteriology and mycology; microbiology and infectious professor in 1984; he was promoted to associate professor diseases); member, USDA grant review panel; president, in 1989 and to full professor in 1994. He also served as vice president, American Society for Rickettsiology; director of the university’s Biotechnology Center, founding and member, Grayson-Jockey Club Research Advisory director of the W. M. Keck Center for Comparative Committee. and Functional Genomics, and founding director of Rikihisa’s career honors include: Innovator of the the Institute for Genomic Biology. He held additional Year Award, OSU; elected fellow, American Academy of appointments at UI’s National Center for Supercomputing Microbiology; elected fellow, The American Association Applications and at the university’s Microelectronics for the Advancement of Science; David White Research Laboratory and Micro and Nanotechnology Laboratory. Award, OSU; Teaching Excellence Award for Graduate Yasuko Rikihisa, Ph.D., AAI ’04 Education, OSU; Emerging and Reemerging Infectious Diseases Award, Human Frontier Science Program, The Ohio State University (OSU) Strasbourg, France; Distinguished Scholar Award, OSU; Professor, Department of Veterinary Biosciences, Pfizer Animal Health Award for Research Excellence, OSU; College of Veterinary Medicine Smith Kline Beecham Award for Research Excellence, OSU; Charles C. Capen Teaching Excellence Award; Japan AAt OSU, Yasuko Rikihisa is Society for Promotion of Science Award; World Bank a member of the Center for Higher Education XVII Award, Midwestern Universities CClinical and Translational Consortium for International Activities; and Teaching SScience, the Center for Microbial Excellence Award, Virginia Polytechnic Institute and State IInterface Biology, the Public University (Virginia Tech). She holds nine U.S. and four HHealth Preparedness for foreign patents. IInfectious Diseases Program, aand the Molecular Genetics, Cell Rikihisa received her M.S. and Ph.D. degrees from the BBiology, and Developmental University of Tokyo and served as a postdoctoral fellow BBiology Program. at Harvard Medical School. She held appointments as assistant and, later, associate professor at the Virginia- She studies intracellular Maryland Regional College of Veterinary Medicine, Virginia Yasuko Rikihisa bbacteria of the Rickettsiales Tech, where she also served as director of the institution’s order, from characterization electron microscope facility. She joined the OSU faculty as of the bacteria themselves to the mechanisms of their associate professor in 1986. transmission to the development of diagnostic products. She has especially focused on Ehrlichia and Anaplasma, Alexander Y. Rudensky, Ph.D., AAI ’94 which can be transferred to farm animals, companion animals, and humans via tick bites. Her analysis of Memorial Sloan-Kettering Cancer Center (MSKCC) immunodominant antigens of the bacteria causing canine HHMI Investigator and Professor, Department of ehrlichiosis has resulted in a commercial diagnostic test Immunology now used annually for parasite screenings of dogs, and AAlexander Rudensky is known additional products to screen for anaplasmosis in dogs are ffor his work on regulatory T cells in development. Rikihisa’s lab also has developed animal ((Tregs), including the molecular models of human and canine ehrlichiosis and Potomac aand cellular mechanisms horse fever and is currently working on a large genomics ggoverning their differentiation project to comprehensively understand the molecular aand function and the roles pathogenesis of ehrlichiosis. tthese cells play in the control of Rikihisa is an associate editor for Frontiers in Cellular aautoimmunity, tumor immunity, and Infection Microbiology, a member of the mBio Board of aand immunity to infections. His Editors, and an ad hoc member of the National Institutes ggroup is particularly interested of Health (NIH) study section and NIH special emphasis iin understanding the role of the panel on bacterial pathogenesis. Her past service Alexander Rudensky ttranscription factor forkhead appointments include: member, NIH study sections box p3 (Foxp3) in establishing Continued on next page www.aai.org AAI Newsletter 9 Members in the News (continued) and maintaining immune homeostasis, as well as School of Medical Sciences of Cornell University. He is a Tri- the plasticity of Treg transcriptional and functional Institutional Professor at MSKCC, the Rockefeller University, programs and the molecular mechanisms of Treg lineage and Cornell University. stability. The overarching goal of the group’s work is to understand the molecular mechanisms governing the Shimon Sakaguchi, M.D., Ph.D., AAI ’90 differentiation and function of CD4+ T cells and their Osaka University Immunology Frontier Research Center role in immunity and tolerance. Professor and Chair, Department of Experimental Rudensky is a past AAI Distinguished Lecturer and Immunology recipient of the AAI-PharMingen Investigator Award. He SShimon Sakaguchi is credited served on the AAI Awards Committee from 2006 to 2009 wwith the discovery of Tregs and and is a past Major Symposium chair and speaker at the mmuch of the subsequent return to AAI annual meeting. ppopularity of suppressor cells in Rudensky has held review and advisory panel iimmunological research. His lab appointments with NIH (immunobiology study section), hhas shown that these naturally National Cancer Institute, Wellcome Trust, Michigan Life ooccurring CD4+CD25+ Tregs are Sciences Corridor, the Cancer Research Institute, EU aactively engaged in controlling SYBILLA Consortium, Damon Runyan Cancer Research a variety of physiological and Fellowship Program, and the international program ppathological immune responses, committee for the 15th International Immunology iincluding autoimmunity, allergy, Congress (Rome, Italy). He is an editorial board member Shimon Sakaguchi ttransplantation tolerance, or reviewer for International Immunology, Cell, Journal and tumor immunity. His of Immunological Methods, Journal of Experimental work addresses the molecular and cellular basis of Treg Medicine, Immunity, Current Immunology Review, development and function, particularly the involvement Proceedings of the National Academy of Sciences USA, of the transcription factor Foxp3, and seeks ways to exploit and Current Opinion in Immunology. He is a past these cells’ activity to control immune responses in clinical member of the Journal of Experimental Medicine settings. In addition, Sakaguchi’s group has developed editorial advisory board and European Journal of a mouse model of spontaneous autoimmune arthritis Immunology executive committee. Rudensky’s resulting from a mutation in the T cell signaling molecule additional career honors include the NIH MERIT Award, ζ-chain-associated protein kinase 70 (ZAP70 ), which Sandler Senior Investigator Award, Searle Scholar Award, results in changes in thymic selection. The group hopes Julius Stone Award, and numerous invited lectureships that analysis of this model will facilitate an understanding at institutions throughout the United States and in of how genetic, environmental, and immunological factors England, Finland, Sweden, Russia, Italy, Israel, Taiwan, act together to induce the development of T cell-mediated and China. autoimmune disease in humans. A biochemistry graduate of the Second Moscow Sakaguchi is a past Major Symposium speaker at State Medical Institute, Rudensky received his Ph.D. the AAI annual meeting and past associate editor for in immunology from the Gabrichevsky Institute for The Journal of Immunology. Other journals for which Epidemiology and Microbiology, Moscow. He undertook Sakaguchi has provided editorial service include Science, postdoctoral training in the Charles Janeway lab at Yale Journal of Experimental Medicine, Immunity, International School of Medicine, where he subsequently served as Immunology, Immunological Reviews, Human Immunology, an associate research scientist. He later held successive Journal of Experimental Pathology, Cancer Immunity, and appointments as assistant, associate, and full professor eLife. His career honors include: The Japan Academy Award; at the University of Washington and served as an adjunct Asahi Prize; the Medal with Purple Ribbon from the Emperor professor at the A. N. Belozersky Institute of Physico- (Japan); Keio Medical Science Prize; Commendation for Chemical Biology, Moscow State University, Russia. Science and Technology, Minister of Education, Culture, He has been an HHMI investigator since 1998, having Sports, Science and Technology, Japan; Takamine Memorial been an assistant investigator since 1993. Appointed an Sankyo Award; Takeda Medical Award; Cancer Research MSKCC member in 2008, Rudensky assumed concurrent Institute’s William B. Coley Award for Basic Immunology professor appointments with the Gerstner Sloan- and Tumor Immunology; Mochida Science Award 2003; and Kettering Graduate School and Weill Cornell Graduate Lucille P. Markey Scholar Award in Biomedical Science.

10 AAI Newsletter July/August 2012 Sakaguchi received his M.D. from Kyoto University, Japan, and trained as a pathology resident at Kyoto University Medical School (KUMS), visiting investigator at the Laboratory of Experimental Pathology, Aichi Cancer Center Research Institute (Nagoya), and senior research fellow at KUMS’ Institute for Immunology. He subsequently obtained his Ph.D. from Kyoto University, focusing on experimental autoimmune disease research. He completed postdoctoral fellowships in immunology/ infectious diseases and in biophysics at Johns Hopkins University and served as a visiting scientist in immunology and rheumatology at Stanford University. He was appointed assistant professor in the Immunology Department at the Scripps Research Institute in 1989. In 1992, Sakaguchi returned to Japan as a Japan Science AAI Entry is Among First FASEB and Technology Agency investigator at RIKEN Institute (Tsukuba) and later headed the Immunopathology Bio-Art Competition Winners Department at Tokyo Metropolitan Institute of Gerontology. From 1999 to 2011, he served as professor An AAI-submitted image took honors in the first and chair of the Experimental Pathology Department at annual FASEB Bio-Art competition. The image, one Kyoto University’s Institute for Frontier Medical Sciences; used on the March 1, 2010, cover of The Journal of from 2007 to 2011, he served as the institute’s director. In Immunology (The JI), was selected as one of the 2011, Sakaguchi assumed his current appointment as a 10 winning entries in the FASEB contest. Viewed professor in the Department of Experimental Immunology, in conjunction with the supporting nontechnical Immunology Frontier Research Center, Osaka University. statement, the submission was deemed by judges to be “both visually arresting and [to] clearly communicate a cutting edge biomedical science concept” to general audiences. The National Academy of Sciences is a private The image is of tissue from a colon biopsy organization of scientists and engineers dedicated stained for Sigirr and other cellular components. to the furtherance of science and its use for the Accompanying the image is text explaining general welfare. It was established in 1863 by that therapeutic targeting of Sigirr could be a congressional act of incorporation signed by useful in the treatment of inflammatory bowel Abraham Lincoln, to serve as an official adviser disease or other inflammatory disorders of the gastrointestinal tract. to the federal government on matters of science or technology. NAS members are selected in The JI covers are selected from among articles recognition of their distinguished and continuing published in each issue. The article yielding the achievements in original research in science and winning image from The JI was by AAI members engineering. Additional information about the Xiaoxia Li (AAI ’09) and Bruce A. Vallance (AAI ’10) Academy and its members is available online at and their co-authors Mohammed Khan, Theodore S. Steiner, Ho Pan Sham, Kirk S. Bergstrom, Jingtian www.NASonline.org. T. Huang, Kiran Assi, Bill Salh, and Isabella T. Tai. To view the winning images, visit www.faseb.org/ Scientific-Image-Competition/Winners.aspx. Contest-winning images were displayed before members of Congress at FASEB’s centennial celebration on May 16 and will be featured on the NIH website and main campus.

www.aai.org AAI Newsletter 11 AAI LOOKS BACK The 1918–1919 Influenza Pandemic as Covered in The Journal of Immunology from 1919 to 1921

he deadly 1918–1919 negative findings, ascribing Tinfluenza pandemic them to improper specimen generated an impressive body collection or culture 2 of immunological research into technique. Nevertheless, the cause and prevention of the inconsistent presence of B. influenzae in patient the disease, and that urgency samples, its presence in is reflected in the many articles healthy individuals, and on influenza published in the isolation of other types The Journal of Immunology of bacteria from influenza from 1919 to 1921. Because patients cast doubt on the bacteria had been shown to be theory that Pfeiffer’s bacillus causative of other infectious was the cause of influenza. diseases, including typhoid William H. Park (AAI 1916, fever and diphtheria, and president 1918), laboratory viruses were not yet understood Demonstration at the Red Cross Emergency Ambulance Station director, New York City as more than filter-passing in Washington, D.C., during the influenza pandemic of 1918, c. 1918, Library of Congress, Prints & Photographs Division Board of Health, Division agents, most scientists of the of Pathology, Bacteriology, time believed the cause of and Disinfection, contended that, to establish etiological influenza to be bacterial. German physician Richard Pfeiffer significance, it was not sufficient merely to establish had isolated bacteria from influenza patients during the the presence of Pfeiffer’s bacillus in all (or nearly all) previous pandemic of 1892 and believed that these bacteria cases of the influenza but that it was also necessary were the cause of influenza; the bacteria had come to be to show that the same strain or type was present in all known as Pfeiffer’s bacillus or Bacillus influenzae or B. cases. Under the direction of Park, Eugenia Valentine influenzae (now Haemophilus influenzae). By the time of (AAI 1920) and Georgia M. Cooper (AAI 1920) injected the 1918 pandemic, many scientists had embraced Pfeiffer’s rabbits with cultures of B. influenzae and tested each hypothesis, and researchers were attempting to establish antiserum against the same (homologous) culture and the etiological significance of B. influenzae to the disease by against other cultures of B. influenzae isolated from examining cases from the unfolding influenza pandemic. the lung, larynx, or trachea of influenza patients.3 They Immunologists cultured and isolated bacteria from were surprised to find a multiplicity of strains and could patient samples, including throat swabs, sputum samples, conclude only that “B. influenzae is not the primary pleural effusions, and lung exudates, with mixed results. etiological agent in epidemic influenza.” The lack of a In 1919, C . Roos from the Mulford Biological Laboratories “hypothetical pandemic strain” was later confirmed by in Glenolden, Pa., reported that a collective review of all similar methods by other investigators, including Arthur influenza samples analyzed by the laboratory beginning F. Coca (AAI 1916, secretary-treasurer 1918–1945, editor- with the epidemic of 1915–1916 identified B. influenzae in in-chief 1920–1948) and Margaret F. Kelley of New York “50 to 90 per cent of the cases.”1 In September and October Hospital and Cornell University.4 Other papers, however, of 1918, Roos specifically examined 33 specimens from presented contradictory findings. In one such paper, F. cases of clinical influenza characterized by a sharp onset and isolated B. influenzae from 27 (82 percent), although M. Huntoon (AAI 1918) and S. Hannum demonstrated streptococci and pneumococci were also commonly that antiserum protected mice from heterologous strains present, being found in 25 (76 percent) and 20 (61 percent) of B. influenzae.5 So it was that, long after the pandemic of the specimens, respectively. Although B. influenzae could subsided, uncertainty remained about whether this not be reproducibly isolated from all cases of influenza microorganism was the primary cause of influenza or examined, Roos and others placed little significance on the whether it was a secondary opportunistic invader.

12 AAI Newsletter July/August 2012 Despite the uncertainty surrounding workw that was funded through a grant the cause of influenza, the lethality of the ffrom the Metropolitan Life Insurance 1918 outbreak lent particular urgency to CCompany. The first issue of The Journal the question of prevention, and a number oof Immunology from 1921 (vol. 6, no. 1) of investigators worked to develop a wwas dedicated exclusively to this topic vaccine against the disease. During the aand the resulting series of papers.7 As height of an influenza epidemic occurring partp of this series, Park and his colleagues in New Orleans in the fall of 1918, Charles testedt combined vaccines made from B. W. Duval and William H. Harris of Tulane influenzaei and strains of streptococcus, University vaccinated approximately five pneumococcus,p and staphylococcus on thousand individuals with a chloroform- 1,5361 employees of the Metropolitan killed B. influenzae preparation.6 LifeL Insurance Company.8 Their results They reported that only 3.3 percent of Street car conductor in Seattle not werew somewhat less striking than the those vaccinated developed influenza, allowing passengers aboard without findings of Duval and Harris, as they a mask, c. 1918, National Archives at compared with 41 percent of the College Park, College Park, MD found no difference in respiratory disease unvaccinated control group. Duval overall (including influenza) between the and Harris concluded that, although the number of inoculated and control groups. However, it was noted that vaccinated persons was few, the results were “interesting the vaccinated group showed the “beneficial influence” of and significant from the standpoint of prophylaxis.” a lower incidence of pneumonia. In New York City, Park, in collaboration with other The cause of influenza would not be definitively members of an influenza commission and the workers resolved until the 1930s, with the isolation of swine of the New York City Department of Health, undertook influenza virus by Shope9 and the subsequent isolation of a comprehensive study of acute respiratory infections— human influenza virus by Smith, Andrewes, and Laidlaw.10 Whereas Pfeiffer’s hypothesis regarding the bacterial 1 C. Roos, “Notes on the Bacteriology, and on the Selective Action of B. influenzae Pfeiffer,” The Journal of Immunology vol 4 (1919): 189–201. cause of influenza was ultimately proven incorrect, it was 2 For instance, Roos pointed out that B. influenzae is “seldom found in the generally agreed then, as now, that most of the deaths from specimens of nasal secretions.” He further noted that he, as a frequent sufferer of common colds, “has been able to demonstrate this fact repeatedly on the 1918–1919 influenza pandemic were due to secondary himself.” bacterial infections11—and that some of the early vaccines 3 Eugenia Valentine and Georgia M. Cooper, “On the Existence of a Multiplicity of Races of B. influenzae As Determined by Agglutination and Agglutinin could have, in fact, prevented the rate of bacterial Absorption,” The Journal of Immunology vol 4 (1919): 359–379. pneumonia and death from the disease.12 4 A.F. Coca and M.F. Kelley, “A Serological Study of the Bacillus of Pfeiffer,” The Journal of Immunology vol 6 (1921): 87–101. Modern influenza research continues to be presented 5 F.M. Huntoon and S. Hannum, “The Role of Bacillus influenzae in Clinical Influenza,” The Journal of Immunology vol 4 (1919): 167–187. in The Journal of Immunology nearly one century after 6 C.W. Duval and W.H. Harris, “The Antigenic Property of the Pfeiffer Bacillus As these early papers appeared in the wake of the 1918 Related to Its Value in the Prophylaxis of Epidemic Influenza,” The Journal of Immunology vol 4 (1919): 317–330. pandemic. Topics of research include the role of innate 7 W.H. Park, A.W. Williams, and C. Krumwiede, “Microbial Studies on Acute immune defenses in protection, the specificity of the T Respiratory Infection with Especial Consideration of Immunological Types,” The Journal of Immunology vol 6 (1921): 1–4. For more on Anna W. Williams, cell memory response, and mechanisms for improving see “Anna Wessels Williams, M.D.: Infectious Disease Pioneer and Public Health vaccination, among others. Contemporary papers Advocate,” AAI Newsletter, March/April 2012, pp. 50–51. 8 A.I. Von Sholly and W.H. Park, “VII. Report on the Prophylactic Vaccination of examine the immune response to recent strains, including 1536 Persons Against Acute Respiratory Diseases, 1919–1920,” The Journal of swine-origin H1N1 influenza virus, the cause of the 2009 Immunology vol 6 (1921): 103–115. 9 R. Shope, “Swine Influenza. III. Filtration Experiments and Etiology,” The Journal pandemic, and highly pathogenic avian H5N1 influenza of Experimental Medicine vol 54 (1931): 373–385. viruses, speculated to be the possible source of a new 10 W. Smith, C. Andrewes, and P. Laidlaw, “A Virus Obtained from Influenza Patients,” Lancet vol 2 (1933): 66–68. pandemic. Much research remains to be done to fully 11 D.M. Morens, J.K. Taubenberger, and A.S. Fauci, “Predominant Role of Bacterial staunch infection and death from seasonal outbreaks and Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness,” The Journal of Infectious Diseases vol 198 future pandemics of the disease, but, if recent research is (2008): 962–970. a fair indicator of future initiatives, immunology as a field 12 Y. Chien, K.P. Klugman, and D.M. Morens, “Efficacy of Whole-Cell Killed Bacterial Vaccines in Preventing Pneumonia and Death during the 1918 Influenza will yield key findings for understanding influenza and Pandemic,” The Journal of Infectious Diseases vol 202 (2010): 1639–1648. limiting the menace it poses to public health. www.aai.org AAI Newsletter 13 ™

AAI Meeting Attendance Hits 12-Year High in Boston

etting the high mark for AAI annual meeting Sattendance since 2000, IMMUNOLOGY 2012™ attracted more than 3,700 registrants.

IMMUNOLOGY 2012™ featured over 700 speakers in 116 sessions. Nearly 1,800 posters were displayed and discussed during dedicated poster hour sessions throughout the week.

The 455 AAI awards presented in connection with the meeting honored scientific achievement and career contributions to the field, recognized service to AAI, and fostered the career development of early- and mid-career scientists. Support included travel awards for all trainee members whose first-author abstracts were selected for oral presentation.

Career-development workshops and networking events addressed the variety, rewards, and challenges of science career options in and beyond research. The exhibit floor was comprised of 129 exhibitors offering a full slate of exhibitor workshops and product showcases. And the lineup of IMMUNOLOGY 2012™ social events again distinguished the AAI annual meeting as the year’s premier gathering and networking event for immunologists and trainees worldwide.

To review the program presented at IMMUNOLOGY 2012™, visit www.IMMUNOLOGY2012.org.

1414 AAIAAAAI NNewsletterewewslsletettteer JJuJuly/Augustulyly/A/Auugguusst 2201200112 2012 AAI ANNUAL MEETING HIGHLIGHTS | MAY 4–8, 2012 | BOSTON, MASSACHUSETTS

AAI President’s Program AAI PRESIDENT’S SYMPOSIUM

AAI PRESIDENT’S ADDRESS

Lawrence Samelson, Amy Andreotti, Leslie Berg, Pamela Schwartzberg, Mark Davis

AAI President Leslie Berg delivering 2012 AAI President’s Address

Leslie Berg with her President’s Address Leslieli Berg withi h President’sid ’ Addressdd attendeesd introducer, U Mass colleague Ken Rock

AAI Distinguished Lectures

Kristin Hogquist, lecturer David Raulet, Leslie Berg

AAI Program Chair Kristin Hogquist, lecturer Vijay Kuchroo, Leslie Berg

Lecturer Anne O’Garra,O’G Kristinii Hogquisti

www.aai.org AAI Newsletter 15 ™

AAI Honors for Career Achievement

AAI LIFETIME ACHIEVEMENT AWARD AAI EXCELLENCE IN MENTORING AWARD

Leslie Berg with awardee Art Weiss Leslie Berg, awardee Max Cooper, Paul Kincade

AAI Scientific, Service Recognition Awards

AAI-Life Technologies Meritorious Career AAI-BD Biosciences Investigator Award Presentation & Lecture Award Presentation & Lecture

Life Technologies’ Jeff Rossio, AAI Executive Director Leslieli Berg, awardeed ShShane CCrotty, BD Bioscience’si i’ Robertb Michele Hogan, awardee Peter Cresswell, Leslie Berg Balderas, Michele Hogan

AAI Award for Human Immunology Research Presentation & Lecture AAI DISTINGUISHED SERVICE AWARD RECIPIENTS

Brian Cobb William Green John Schreiber

Leslie Berg, awardee John Atkinson

16 AAI Newsletter July/August 2012 2012 AAI ANNUAL MEETING HIGHLIGHTS | MAY 4–8, 2012 | BOSTON, MASSACHUSETTS

AAI Professional Development Awards

Pfizer-Showell Award Lustgarten-eBioscience Memorial Award

Michele Hogan, awardee Joseph C. Sun, Leslie Berg eBioscience’s Tony Ward,d awardeed Lihuaih Chen,h Leslie Berg

Chambers-eBioscience Memorial Award AAI-Life Technologies Trainee Achievement Awards

Tony Ward,d awardeed Rajeshj h K. ShSharma AAI-Life Technologies Trainee Achievement Award recipients Burton Barnett, Rebecca Mathew, Jakob von Moltke, Caroline Padro, Jarish Cohen, Chao Ma

Pictured with Michele Hogan (front row, third from right), twelve winners of AAI Early Career Faculty, Undergraduate Faculty, and Laboratory Travel Grants – front row (L-R): Emiko Mizoguchi, Mahyar Nouri-Shirazi, Yong Liang Zhang, Pornpimon Angkasekwinai, Lisa Ryan, Kara Lukin and (back row) Damian Turner, Greg Swan, Sophia Sarafova, Nathalie Scholler, Susan Jarvi, Roza Nurieva www.aai.org AAI Newsletter 17 ™

AAI Poster Sessions

AAI Career Development Sessions

AAI Education Committee & AAI Committee on the Status of Women— Careers in Science Lecture & Roundtable

Olja Finn delivering keynote address, “Make an effort! A path to a rewarding life in science” (at right) and joining the Research Careers in Academia table discussion (below)

AAI Committee on the Status of Women member Janis Burkhardt serving asdiscussion co-leader at theNew PI: Attracting Students and Postdocs, Preparing for Tenure table

18 AAI Newsletter July/August 2012 2012 AAI ANNUAL MEETING HIGHLIGHTS | MAY 4–8, 2012 | BOSTON, MASSACHUSETTS

AAI Career Development Sessions (Continued)

AAI Minority Affairs Committee Careers and Networking Roundtable

Above left: MAC Roundtable attendees discussing career iissues; aboveb right:i h MAC table leader Charles Egwuagu, who also delivered the AAI Minority Affairs Committee Guest Lecture (Regulation of autoreactive lymphocytes that mediate CNS autoimmune diseases)

Attendees at the sold out Careers in Biotech Panel Discussion and Networking Reception Instructor Derek Haseltine providing individual counseling following the How to Convert Your CV into a Resumé careers session

Careers in Biotech session panelists Andy Kokaji, Art Tzianabos, Olivia Schneider, Chris Schwab Attendees at the Secrets to a Successful Postdoc workshop www.aai.org AAI Newsletter 19 ™

Social Events OPENING NIGHT RECEPTION Sponsored by eBioscience NEW MEMBER RECEPTION Sponsored by AAI Membership Committee

AAII Secretary-TreasurerS T MitchMih KronenbergK b helping welcome guests at the reception for Jugglers (above), twirlers (right), new AAI members and attendees enjoying the festive atmosphere at the reception kicking off IMMUNOLOGY 2012™ PRESIDENT’S SERVICE APPRECIATION RECEPTION Sponsored by BioLegend

Leslie Berg thanking AAI AAI GALA—CASINO NIGHT IN THE BACK BAY volunteers, including members Sponsored by BioLegend of Council and committees, abstract programming chairs, The JI editors and reviewers, BioLegend founder Gene AAI course instructors, and Lay and a door prize winner others (inset) pictured at the Casino Night in the Back Bay event

At right, BioLegend founder Gene Lay (right) with colleague Craig Monell; below, Michele Hogan, Gerry Sonnenfeld, Olja Finn

20 AAI Newsletter July/August 2012 2012 AAI ANNUAL MEETING HIGHLIGHTS | MAY 4–8, 2012 | BOSTON, MASSACHUSETTS

Exhibit Hall

AAI COUNCIL MEETING

AAII CCouncilill membersb KristinKi i HHogquist,i JerryJ BBoss, MiMichele h l Hogan, Jeff Frelinger, Leslie Berg, Marc Jenkins, Gail Bishop, Mitch Kronenberg, Arlene Sharpe

See you next year! Celebrating

100IMMUNOLOGY Ye a r s2013™ Meeting Dates: May 3 – 7, 2013 Exhibit Dates: May 4 – 6, 2013 Hawaii Convention Center Michele Hogan with representatives of the Honolulu, Hawaii Visitors & Convention Bureau of Hawaii, site of IMMUNOLOGY 2013™ and the AAI Centennial celebration www.aai.org AAI Newsletter 21 IMMUNOLOGY 2012™ SPONSORS Thank you to our Sponsors

PLATINUM SPONSORS

N IMMUNOLOGY 2012™ Gala N Chambers-eBioscience Memorial Award N President’s Service Appreciation Reception N Lustgarten-eBioscience Memorial Award N Opening Night Welcome Reception N Meeting Bags

GOLD SPONSOR SILVER SPONSORS

N AAI-BD Biosciences Investigator Award N AAI Early Career Faculty Travel Grants N AAI-Life Technologies MARC: Maximizing Access to Research Careers N AAI Trainee Abstract Awards Meritorious Career Award N AAI Minority Scientist Travel Awards N Careers in Science Lecture N AAI-Life Technologies N Support for Minority Affairs and Roundtable Trainee Achievement Awards Committee Guest Lecture N Program Support SUPPORTING SPONSORS

N Cyber Café N The JI Editorial Board Dinner and Meeting N General Meeting Support N Literature CONTRIBUTING SPONSORS

ALLCELLSALLCELLS N Support for AAI Trainee N Support for N Support for AAI Early Career Abstract Awards N Refreshment Cart AAI Trainee Abstract Awards Faculty Travel Grants N Support for AAI Laboratory Travel Grants

N Cyber Cafe´ N Refreshment Cart N Literature Henry J. Showell N Support for AAI Trainee N Pfizer-Showell Travel Award Abstract Awards N Literature OTHER SUPPORTERS Genocea Biosciences IMGENEX Corporation Mickie and Leon Berg, Eric Berg N Support for AAI Trainee Abstract Awards N Support for AAI Trainee Abstract Awards N Meeting Support in Honor of AAI President Leslie J. Berg

22 AAI Newsletter July/August 2012 www.aai.org AAI Newsletter 23 GRANT AND AWARD DEADLINES

Prize/Award July 31—American Association for the Presented annually, this international award con- Advancement of Science (AAAS) Mentor sists of a $35,000 prize and a luncheon in honor of Awards the recipient. The recipient delivers an honorary Description lecture as part of The Rockefeller University Lecture The two categories of the AAAS Mentor Awards Series. (Lifetime Mentor Award and Mentor Award) both honor individuals who, during their careers, dem- Eligibility onstrate extraordinary leadership to increase the The Wiley Foundation invites and encourages the participation of underrepresented groups in science nomination of exceptional scientists or research and engineering fields and careers. These groups teams whose research has set the standard for excel- include: women of all racial or ethnic groups; lence. International nominations are encouraged. African American, Native American, and Hispanic Nomination men; and people with disabilities. Nominations, which should be submitted by Prize/Award someone other than the nominee, are accepted by A prize of $5,000 is awarded to the Lifetime Mentor mail or e-mail submission and must be received by Award recipient, who will have served in the role July 31. of mentor for 25 or more years. A prize of $5,000 is Details: www.wiley.com/WileyCDA/Section/ awarded to the Mentor Award recipient, who will id-390111.html have served in the role of mentor for less than 25 Contact: [email protected] years. Eligibility August 1—AAAS Kavli Science Journalism The award is open to all, regardless of nationality Awards or citizenship. Nominees must be living at the time Description of their nomination. The AAAS Kavli Science Journalism Awards repre- Nomination sent the pinnacle of achievement for professional Nominations are accepted by e-mail submission journalists in the science writing field. Since 1945, and must be received by July 31. the awards have recognized outstanding report- ing for a general audience and honored individuals Details: www.aaas.org/aboutaaas/awards/mentor (rather than institutions, publishers, or employers) Contact: [email protected] or [email protected] for their coverage of the sciences, engineering, and mathematics. July 31—The Wiley Prize in Biomedical Prize/Award Sciences The award for each category is $3,000 and includes Description reimbursement for AAAS annual meeting travel and The Wiley Prize in Biomedical Sciences is intended hotel expenses to attend the prize presentation. to recognize breakthrough studies in pure or applied life science research that are distinguished by excel- Eligibility lence and originality and impact on our understand- Winning journalists are those who have helped ing of biological systems and processes. The award foster the public’s understanding and appreciation may recognize a specific contribution or series of of science. Journalists and their entries are selected contributions that demonstrate the nominee’s sig- based on scientific accuracy, initiative, original- nificant leadership in the development of research ity, clarity of interpretation, and value in fostering concepts or their clinical application. Particular public understanding of science. emphasis will be placed on research that champions Nomination novel approaches and challenges accepted thinking Nominations are accepted by mail and must be in the biomedical sciences. received by August 1. Details: www.aaas.org/aboutaaas/awards/sja/ Contact: (202) 326-6440 Continued on next page

24 AAI Newsletter July/August 2012 GRANT AND AWARD DEADLINES

Eligibilityccomplished early-career investigators at the August 1—American College of Rheumatology Threeassistant prizes professor will be awarded level may to apply young for biomedi- the Research and Education Foundation (REF) A Burroughscal scientists Wellcome who demonstrate Fund (BWF) outstandingInvestigators early in the Awards and Grants Program Pathogenesisachievement of through Infectious work Disease in basic, program, applied, which and/ Description providesor translational opportunities biomedical to bring science. multidisciplinary To be eligible, This program exists to train and develop rheuma- approachesan applicant to themust: study have of beenhuman born infectious outside diseases.of the tologists and rheumatology health professionals ThisUnited award States, provides on or $500,000 after January over a 1, period 1974; ofbe five a natu- and nurture novel research ideas for the future. The years.ralized U.S. citizen or permanent resident (green awards are designed to identify the best scientists card holder); have earned a doctoral degree (M.D., in each niche of rheumatology, foster their ideas, The program supports research on the pathogenesisPh.D., or equivalent); of infectious intend disease to pursue at its most a profes- and prepare them for larger awards and grants sional career in the United States; and hold a full- from other institutions to sustain their long-term fundamental level, the points where human and microbialtime position systems in anconnect, academic to shed or other light institutionon how at careers as rheumatologists and rheumatology health the level of assistant or associate professor, research professionals. human hosts handle infectious challenge. Funding aimsscientist, to illuminate or equivalent. the fundamentals that affect Prize/Award theApplication outcomes of this encounter: how colonization, The program offers research and education oppor- infection,Applications commensalism, are accessed, and completed, other relationships and submit- tunities for clinicians, students, health professionals, ted via the online Vilcek Foundation application researchers, and academic institutions. Grants of system and must be received by August 14. one-, two-, and three-year funding range in amounts by program from $50,000 to $375,000 annually. Details: www.vilcek.org/prizes/creative-promise/ index.html Eligibility Contact: (212) 472-2500; [email protected] Eligibility extends variously by award program to Vannevar Bush Award fellows and early- to mid-career physicians and AugustNominations 15—AAAS Award Due for November Public 2 health professionals. Engagement with Science Application Descriptionhe National Science Board (NSB) invites All applications must be submitted online and are TEstablishednominations in 1987for the as Vannevarthe AAAS BushAward Award, for Public which due by 5:00 PM Eastern Daylight Time on August 1. recognizesUnderstanding exceptional of Science service and to Technology, the nation in this science The online Call for Applications brochure* provides andaward technology. is given Theannually award to honors scientists truly or exceptional engineers information on each award and grant opportunity, lifelongwho, while leaders working in science in their and fields, technology make whooutstanding have with applications available online via the individual madecontributions substantial to contributions the popularization to the ofwelfare science. of the award pages. nation through public service activities in science, technology,Prize/Award and public policy. *www.rheumatology.org/ref/awards/REF_CFA_ The recipient receives a monetary prize of $5,000, Candidates for the Vannevar Bush Award should Brochure.pdf#toolbar=1 a commemorative plaque, and reimbursement for have demonstrated outstanding leadership and Details: www.rheumatology.org/REF/awards/index. AAAS annual meeting registration, travel, and hotel accomplishment in meeting at least two of the asp expenses to attend the prize presentation. following selection criteria: Contact: (404) 633-3777; [email protected] Eligibility N Candidates must be U.S. citizens Eligible individuals include scientists and engineers August 14—The Vilcek Prize for Creative N (individual Distinguished or a himself/herself small group) from through all disciplines, public Promise in Biomedical Science includingservice activities social and in science behavioral and sciencestechnology and bio- Description N medical Pioneered fields, the exploration,who have contributed charting, and substantially settlement The Vilcek Foundation awards the Creative Promise toof thenew public’s frontiers engagement in science, withtechnology, science education, or technol- Prize in Biomedical Science to recognize foreign- ogy.and Onlypublic materials service produced for general audiences, born scientists who, early in their careers, have as opposed to professional or trade audiences, will N Demonstrated leadership and creativity that have demonstrated exceptional achievement in biomedi- be considered. Types of activities to be considered inspired others to distinguished careers in science cal science. include books, magazines, and newspaper articles; and technology broadcasting; lecturing; museum presentation Prize/Award N and Contributed exhibit design; to the andwelfare other of public-outreachthe Nation and Recipients each receive $35,000 and a commemora- activities,mankind throughwhether activitieslocal, national, in science or international. and tive plaque, presented at the foundation’s annual technology awards dinner held in early spring in New York City. Continued next next page www.aai.org AAI Newsletter 25 GRANT AND AWARD DEADLINES (continued)

Nominators are encouraged to identify candidates this award honors an individual or a limited number whose contributions reach broad audiences that of individuals working together in the scientific or include women, minorities, persons with disabili- engineering community for making an outstanding ties, and senior citizens. contribution to furthering science diplomacy. Nomination Prize/Award Nominations are accepted by mail or e-mail and The awardee receives a prize of $5,000, a com- must be submitted by August 15. memorative plaque, and AAAS annual meeting Details: www.aaas.org/aboutaaas/awards/public/ registration, housing, and travel to attend the prize presentation. Contact: [email protected] Eligibility August 15—Foundation for the National The award is open to all, regardless of nationality or Institutes of Health (FNIH) Lurie Prize in the citizenship. Nominees must be living at the time of Biomedical Sciences their nomination. Any individual or small group in Description the scientific and engineering community that has In 2013, the FNIH will present the first Lurie Prize, contributed to the role of science cooperation in an annual award recognizing outstanding achieve- building stronger links between and among societ- ment by a promising young scientist in biomedical ies is eligible for this award. research. Nomination Prize/Award Nominations are accepted by mail or fax and must The prize amount is $100,000, to be used as the be received by September 1. awardee chooses. The award will be presented in the Details: www.aaas.org/aboutaaas/awards/int/ spring of 2013 in Washington, DC. Contact: [email protected] Eligibility Any outstanding young biomedical investigator who September 1—AAAS Philip Hauge Abelson will not have passed his/her 52nd birthday on April Award 12, 2013, is eligible to be nominated. Description This award is presented annually either to a public Nomination servant, in recognition of sustained exceptional Nominations must be submitted via the Lurie contributions to advancing science, or to a scientist Prize online nomination site by 1:00 PM Eastern whose career has been distinguished both for scien- Daylight Time on August 15. Self-nominations are tific achievement and for other notable services to not accepted. A member of any accredited educa- the scientific community. tional and/or scientific institution may submit a nomination, without limit on the number of nomi- Prize/Award nations that may derive from a single nominator or The awardee receives a prize of $5,000, a com- institution. memorative plaque, and AAAS annual meeting Details: www.fnih.org/content/lurie-prize- registration, housing, and travel to attend the prize biomedical-sciences presentation. Contact: [email protected] Eligibility Any public servant or scientist embodying the September 1—AAAS Award for Science criteria in the above award description is eligible Diplomacy to be nominated. Description Nomination Formerly known as the AAAS Award for International Nominations are accepted by mail, fax, or e-mail Scientific Cooperation, this award recognizes sci- and must be received by September 1. entists and engineers who contribute valuable time Details: www.aaas.org/aboutaaas/awards/abelson/ away from the established career paths of research, teaching, and publishing to foster activities and Contact: (202) 326-6600; [email protected] develop programs that address key science ques- tions and build important societal links. Specifically, Continued on next page

26 AAI Newsletter July/August 2012 GRANT AND AWARD DEADLINES

September 1—AAAS Award for Scientific September 4—Burroughs Wellcome Fund Freedom and Responsibility Career Awards at the Scientific Interface Description Description This award is presented annually to honor scien- These awards provide funding to bridge advanced tists and engineers whose exemplary actions have postdoctoral training and the first three years of served to foster scientific freedom and responsibil- faculty service. They are intended to foster the early ity. Specifically, it recognizes those who have acted career development of researchers who have tran- to protect the public’s health, safety, or welfare; sitioned or are transitioning from undergraduate focused public attention on important potential and/or graduate work in the physical/mathemati- impacts of science and technology on society by cal/computational sciences or engineering into their responsible participation in public policy postdoctoral work in the biological sciences and debates; or established important precedents in car- who are dedicated to pursuing a career in academic rying out the social responsibilities or in defending research. the professional freedom of scientists and engineers. Prize/Award Prize/Award The awards provide $500,000 over five years to The awardee receives a prize of $5,000, a com- support up to two years of advanced postdoc- memorative plaque, and AAAS annual meeting toral training and the first three years of a faculty registration, housing, and travel to attend the prize appointment. presentation. Eligibility Eligibility These awards are open to U.S. and Canadian The award is open to all, regardless of nationality citizens or permanent residents as well as to U.S. or citizenship, and seeks to inspire the next genera- temporary residents. Eligible candidates may self- tion of scientists and engineers as they begin their nominate by submitting a preproposal application. careers. An online eligibility quiz screens prospective appli- cants and serves as a portal to the online application Nomination for those eligible to proceed. Nominations may be submitted by mail, fax, or e-mail and must be received by September 1. Application Details: www.aaas.org/aboutaaas/awards/freedom/ Only electronic applications are accepted. The preproposal application deadline is 4:00 PM Eastern Contact: (202) 326-6794; [email protected] Daylight Time on September 4. (The subsequent, invited application deadline is 4:00 PM Eastern Standard Time on January 10, 2013.) Details: www.bwfund.org/pages/558/Career- Awards-at-the-Scientific-Interface/ Contact: (919) 991-5116; [email protected]

AAI Newsletter: Members in the News—Submissions Invited AAI welcomes the opportunity to highlight the career achievements and professional honors attained by AAI member scientists. Such publicity not only serves to inspire colleagues but also informs the broader public of immunology’s vital and widening role in scientific discovery and transformative medicine. Help AAI share news of your or another member’s noteworthy scientific and/or service recognition or career appointment by contacting [email protected]. Thank you!

www.aai.org AAI Newsletter 27 Meetings and Events Calendar

Mark Your Calendar for These Important Dates!

2012

July 19–23, 2012 October 3–6, 2012 Society for Developmental Biology Biennial Meeting of the European Society 71st Annual Meeting for Immunodeficiencies (ESID 2012) Montreal, Canada Florence, Italy www.sdbonline.org/2012Mtg.htm www2.kenes.com/esid2012/Pages/Home.aspx

July 21–25, 2012 October 4–8, 2012 November 6–10, 2012 The American Society for Virology 31st Transcriptional Regulation: Chromatin American Society of Human Genetics Annual Scientific Meeting and RNA Polymerase II San Francisco, California University of Wisconsin–Madison, Madison, Snowbird, Utah Contact: [email protected] Wisconsin www.asbmb.org/ASBMBMeetings/ www.asv.org SpecialSymposia/symposia.aspx?mid=24 November 11–15, 2012 American Society of Tropical Medicine July 22–28, 2012 October 9–11, 2012 and Hygiene (ASTMH) 61st Annual 20th Annual International Conference on La Jolla Immunology Conference Meeting Composites or Nano Engineering La Jolla, California Atlanta, Georgia Beijing, China www.astmh.org/Home.htm www.icce-nano.org October 11–14, 2012 Post Translational Modifications: November 16–19, 2012 July 29–August 3, 2012 Detection and Physiological Role AIC 2012: 41st Annual Autumn AAI Advanced Course in Immunology Tahoe City, California Immunology Conference Boston, Massachusetts www.asbmb.org/ASBMBMeetings/ Chicago, Illinois http://aai.org/Education/Courses/ SpecialSymposia/symposia.aspx?mid=25 http://autumnimmunology.org Advanced/index.html October 12–16, 2012 November 28–December 1, 2012 August 19 – 21, 2012 ASBMR 34th Annual Meeting 6th Asian Congress of Pediatric Infectious Minneapolis, Minnesota Diseases (ACPID 2012) Cell Symposia on Human Immunity www.asbmr.org Colombo, Sri Lanka Sheraton Lisboa, Lisbon, Portugal www.acpid2012.org www.cell-symposia-human-immunity.com October 21–24, 2012 December 2–4, 2012 September 4–9, 2012 14th Annual Upstate New York Immunology Conference 2012 CRWAD Meeting: Conference of Frontiers in Lipid Biology Bolton Landing, New York Research Workers in Animal Diseases/ Banff, Alberta, Canada www.amc.edu/NYIC/index.html American Association of Veterinary www.asbmb.org/ASBMBMeetings/ Immunologists SpecialSymposia/symposia.aspx?mid=23 October 27–28, 2012 Chicago, Illinois www.cvmbs.colostate.edu/mip/crwad September 5–8, 2012 New England Immunology Conference Woods Hole, Massachusetts European Congress of Immunology 2012 http://neic.uchc.edu December 15–19, 2012 Glasgow, Scotland 2012 American Society for Cell Biology http://eci-glasgow2012.com October 28–30, 2012 Annual Meeting San Francisco, California September 11–15, 2012 45th Annual Meeting of the Society for Leukocyte Biology, “Inflammation in Regular Abstract Submission Deadline for 10th Joint ICS/ISICR Meeting—Cytokines: Innate Immunity and Adaptive Immune Minisymposium talk: July 30, 2012 From Basic Biology to Clinical Application Mechanisms” www.ascb.org Geneva Switzerland Grand Wailea, Maui, Hawaii www.cytokines2012.com www.leukocytebiology.org

September 12–14, 2012 November 4–9, 2012 Colorado Immunology Conference ThymUS 2012 International Conference Vail, Colorado Sunny Isles Beach, Florida www.thymus-conference.org September 25–28, 2012 Alternatives to Antibiotics (ATA) Paris, France www.alternativestoantibiotics.org

28 AAI Newsletter July/August 2012 2013 January 13–18, 2013 May 19–23, 2013 May 17–21, 2014 Immunology of Fungal Infections CYTO 2013 (International Society CYTO 2014 (International Society Gordon Research Conference for Advancement of Cytometry) for Advancement of Cytometry) Galveston, Texas San Diego, California Ft. Lauderdale, Florida www.grc.org/programs. Contact: [email protected] Contact: [email protected] aspx?year=2013&program=fungal July 7–10, 2013 June 21–25, 2014 January 20–25, 2013 14th International TNF Conference The American Society for Virology The 2nd NIF (Network of Immunology Loews Le Concorde 33rd Annual Scientific Meeting Frontiers) Winter School on Advanced Quebec City, Quebec, Canada Colorado State University Immunology www.tnf2013.com Fort Collins, Colorado Singapore Country Club, Singapore www.asv.org http://ifrec-sign-winterschool.org July 20–24, 2013 The American Society for Virology September 12–16, 2014 January 26–29, 2013 32nd Annual Scientific Meeting ASBMR 36th Annual Meeting 52nd Midwinter Conference Pennsylvania State University Houston, Texas of Immunologists State College, Pennsylvania www.asbmr.org Pacific Grove, California www.asv.org www.midwconfimmunol.org 2015 August 22–27, 2013 February 13–17, 2013 15th International Congress February 11–15, 2015 52013 BMT Tandem Meeting of Immunology 2015 BMT Tandem Meeting Salt Lake City, Utah Milan, Italy San Diego, CA www.cibmtr.org/Meetings/Tandem/index. www.ici2013.org www.cibmtr.org/Meetings/Tandem/index.html html October 4–8, 2013 April 5–8, 2013 March 28 – April 1, 2015 ASBMR 35th Annual Meeting Experimental Biology (EB) (APS, Canadian Society for Immunology Baltimore, Maryland 26th Annual Spring Meeting ASPET, ASIP, ASN, AAA, ASBMB) www.asbmr.org Boston, Massachusetts TELUS Whistler Conference Centre Contact: [email protected] Whistler, British Columbia, Canada October 10–13, 2013 www.csi-sci.ca 13th International Workshop May 8–12, 2015 on Langerhans Cells April 20–24, 2013 ™ Royal Tropical Institute IMMUNOLOGY 2015 , AAI Annual Experimental Biology (EB) (APS, Amsterdam, The Netherlands Meeting ASBMB, ASPET, ASIP, ASN, AAA) www.lc2013.nl New Orleans, Louisiana Boston, Massachusetts http://aai.orgMeetings/Future_Meeting. Contact: [email protected] 2014 html May 3–7, 2013 February 19–23, 2014 July 11–15, 2015 ™ IMMUNOLOGY 2013 , AAI Annual 2014 BMT Tandem Meeting The American Society for Virology Meeting and AAI Centennial Orlando, Florida 34rd Annual Scientific Meeting Celebration The University of Western Ontario www.cibmtr.org/Meetings/Tandem/index.html Honolulu, Hawaii London, Ontario, Canada www.immunology2013.org April 26–30, 2014 www.asv.org Experimental Biology (EB) (APS, October 9–13, 2015 May 18–21, 2013 ASPET, ASIP, ASN, AAA, ASBMB) 2013 American Transplant Congress San Diego, California ASBMR 37th Annual Meeting (AST) Contact: [email protected] Seattle, Washington Seattle, Washington www.asbmr.org www.atcmeeting.org May 2–6, 2014 IMMUNOLOGY 2014™, AAI Annual Meeting Pittsburgh, Pennsylvania http://aai.org/Meetings/Future_Meeting. html

www.aai.org AAI Newsletter 29 AAI Public Affairs ONLINE

Visit us to s ,EARNABOUT.)(FUNDING s +EEPCURRENTONKEYPOLICY ISSUES s $ISCOVERHOWYOUCANHELP !!)INITSADVOCACYINITIATIVES 'OTOwww.aai.org ANDCLICKON Public Affairs.

Get a GRIP: An AAI program designed to help new investigators prepare their NIH grant proposals AAI is pleased to offer a program to match new PI’s with established PI’s who have significant, successful grant writing careers. The Grant Review for Immunologists Program (GRIP) invites new PI’s to submit an outline or NIH-style abstract to the GRIP coordinator who, with the assistance of a small volunteer subcommittee, will attempt to match the topic of the proposal with the research experience of an established PI. Matches will be made as quickly as possible to allow new PI’s to meet upcoming NIH grant deadlines. Participation is strictly voluntary and is not intended to supplant internal mentoring programs. GRIP is now accepting both new PI and established PI participants. Please send your CV and a brief description of either your potential research project (new PI’s) or grant reviewing experience (established PI’s) to [email protected] (please write “GRIP” in the subject line). Program details at www.aai.org/GRIP_rd.htm

30 AAI Newsletter July/August 2012

NONPROFIT ORG. THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS NONPROFIT ORG. US POSTAGE PAID 9650 Rockville Pike, Bethesda, MD 20814-3994 US POSTAGE PAID YORK PA YORK PA PERMIT 356 PERMIT 356

Future AAI Annual Meetings Mark Your Calendar for the Premier Annual Immunology Event!

Hawaii Tourism Authority (HTA)/Tor Johnson IMMUNOLOGY 2013™ IMMUNOLOGY 2014™ IMMUNOLOGY 2015™ May 3–7 May 2–6 May 8–12 Honolulu, Hawaii Pittsburgh, Pennsylvania New Orleans, Louisiana AAI Centennial Meeting